Prophylactic cranial irradiation in lung cancer

Area of Science:

• Oncology
• Radiation Oncology
• Neuro-oncology

Background:

• Locally advanced lung cancer presents risks of local, regional, and distant failure.
• The brain is a common site for relapse, especially with improved locoregional and systemic control.
• Preventing brain metastases is a critical focus in lung cancer management.

Purpose of the Study:

• To evaluate the efficacy of prophylactic cranial irradiation (PCI) in reducing brain relapse in lung cancer patients.
• To review the evidence for PCI in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
• To discuss the risks and benefits of PCI, including neurocognitive toxicity.

Main Methods:

• Meta-analysis of existing trials for SCLC.
• Review of prospective trials and long-term data for NSCLC.
• Analysis of overall survival, disease-free survival, and toxicity profiles.

Main Results:

• PCI significantly improves overall and disease-free survival in SCLC patients in complete remission.
• Long-term neurocognitive impairments are rare with modern PCI protocols.
• Comparable risks of brain relapse are observed in long-term survivors with locally advanced stage III NSCLC.

Conclusions:

• PCI is the standard of care for limited-stage SCLC in complete remission, with conventional fractionation around 30 Gy preferred.
• Further investigation of PCI in locally advanced NSCLC is warranted through well-designed clinical trials.
• Optimizing PCI dose and fractionation remains an area for future research.